...Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals... ...Kettering Cancer Center, and Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc.... ...company’s near-term plans. Targets: CD73 (NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor
Elizabeth S. Eaton, Staff Writer
ORIC-101
Aragon Pharmaceuticals Inc.
Ignyta...
...thought the companies were worth even more and thus bid more." First to go was Aragon Pharmaceuticals Inc.... ...High-affinity variants of signal regulatory protein alpha (SIRPA) to treat cancer 5/1/15 Series A $36.0 Aragon Pharmaceuticals Inc....
...preclinical development for castration-resistant prostate cancer (CRPC). Many of Oric's investors previously put money into Aragon Pharmaceuticals Inc....
...Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals... ...Kettering Cancer Center, and Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc.... ...company’s near-term plans. Targets: CD73 (NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor
Elizabeth S. Eaton, Staff Writer
ORIC-101
Aragon Pharmaceuticals Inc.
Ignyta...
...thought the companies were worth even more and thus bid more." First to go was Aragon Pharmaceuticals Inc.... ...High-affinity variants of signal regulatory protein alpha (SIRPA) to treat cancer 5/1/15 Series A $36.0 Aragon Pharmaceuticals Inc....
...preclinical development for castration-resistant prostate cancer (CRPC). Many of Oric's investors previously put money into Aragon Pharmaceuticals Inc....